Latest news with #HANGZHOU
Yahoo
13 hours ago
- Entertainment
- Yahoo
"Silk and the Silk Road" Exhibition from China National Silk Museum Debuts in Kazakhstan
HANGZHOU, China, June 18, 2025 /PRNewswire/ -- In a vibrant celebration of cultural exchange, the "Silk and the Silk Road: From China to Kazakhstan" exhibition opened at the National Museum of Kazakhstan on June 16. This flagship event of Kazakhstan's "China Tourism Year" coincides with the second China-Central Asia Summit, marking a significant new chapter in cross-cultural dialogue. The opening ceremony wooed attendees with a fusion of Chinese and Kazakh artistic traditions – from the timeless melody of "High Mountains and Flowing Water" on the Guqin (traditional Chinese musical instrument) to the energetic Kazakh dance. A showstopping fashion presentation featured models in exquisite Hanfu (traditional Chinese dress) alongside Kazakh national costumes, creating a visual dialogue across centuries. Highlights of the exhibition include 145 rare artifacts tracing 2,000 years of silk history, three immersive sections: The Birth of Silk, Routes That Changed the World, and Silk in Daily Life. Star exhibits feature 8th-century textiles that showcase extraordinary craftsmanship, adorned with motifs reflecting the rich cultural fusion along the ancient trade routes. Visitors can also experience living traditions through "Beyond the Mulberry Fields: China Sericulture Intangible Cultural Heritages" – interactive demonstrations of UNESCO-listed silk techniques like kesi (silk tapestry) and intricate embroidery by master artisans. Beyond the gallery, scholars from both nations are convening to discuss the preservation of textile heritage, while Hanfu cultural activities bring ancient fashions to life across Astana. The exhibition forms part of China National Silk Museum's Global Showcase programme, with previous shows from seven countries including among others, France, Hungary and Uzbekistan. "These silks are more than artifacts – they're threads connecting our shared history," remarked Zhang Chengming, the museum deputy director during the opening. The exhibition runs through August 8, offering visitors a rare opportunity to witness the enduring legacy of the Silk Roads. Contact: Jinfang Lilijinfang@ View original content to download multimedia: SOURCE China National Silk Museum
Associated Press
27-05-2025
- Business
- Associated Press
ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia
HANGZHOU, China, May 26, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. ('Zylox-Tonbridge' or the 'Company') today announced that its proprietary ZYLOX Unicorn™ Vascular Closure Device (VCD) has received regulatory approval in Indonesia. This marks the ZYLOX Unicorn™ Vascular Closure Device's first international market clearance and the Company's first market authorization in Southeast Asia—representing a significant step forward in its international expansion strategy. As China's first domestically developed vascular closure device, the ZYLOX Unicorn™ VCD offers an extended closure range from 5F to 22F and is compatible with large-bore access sites (≥8F), enabling broader clinical applications and addressing previously unmet needs in vascular intervention. Designed to meet global standards, the ZYLOX Unicorn™ VCD has demonstrated strong safety and efficacy in premarket clinical trials. The system facilitates effective vascular closure, shortens patient immobilization time, and reduces the risk of puncture-site complications—delivering high-quality, affordable care to a wider patient population. The product was granted marketing authorization in China in June 2024. Indonesia, the world's fourth most populous country, represents a major opportunity for expanding access to advanced vascular intervention solutions. The approval of the ZYLOX Unicorn™ VCD in this key market will provide local physicians and patients with greater access to comprehensive vascular intervention solutions and support Zylox-Tonbridge's continued expansion across Southeast Asia. Zylox-Tonbridge's overseas business has grown rapidly in recent years, generating approximately USD 3.1 million in revenue in 2024, with a four-year compound annual growth rate (CAGR) of 87%. The Company's business footprint spans Europe, the Americas, the Middle East, and Africa, covering countries such as France, Germany, Italy, Spain, Turkey, Saudi Arabia, Argentina, Brazil, and South Africa. In 2025, Zylox-Tonbridge showcased key products at major global congresses including LINC, PAIRS, CICE, and ESOC, boosting its international brand visibility. Looking ahead, Zylox-Tonbridge remains committed to its mission of 'Innovation for Quality Life' and will continue expanding global access to high-quality, affordable treatment solutions through enhanced localization and strategic market entry. View original content: SOURCE ZYLOX-TONBRIDGE
Yahoo
27-05-2025
- Business
- Yahoo
ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia
HANGZHOU, China, May 26, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or the "Company") today announced that its proprietary ZYLOX Unicorn™ Vascular Closure Device (VCD) has received regulatory approval in Indonesia. This marks the ZYLOX Unicorn™ Vascular Closure Device's first international market clearance and the Company's first market authorization in Southeast Asia—representing a significant step forward in its international expansion strategy. As China's first domestically developed vascular closure device, the ZYLOX Unicorn™ VCD offers an extended closure range from 5F to 22F and is compatible with large-bore access sites (≥8F), enabling broader clinical applications and addressing previously unmet needs in vascular intervention. Designed to meet global standards, the ZYLOX Unicorn™ VCD has demonstrated strong safety and efficacy in premarket clinical trials. The system facilitates effective vascular closure, shortens patient immobilization time, and reduces the risk of puncture-site complications—delivering high-quality, affordable care to a wider patient population. The product was granted marketing authorization in China in June 2024. Indonesia, the world's fourth most populous country, represents a major opportunity for expanding access to advanced vascular intervention solutions. The approval of the ZYLOX Unicorn™ VCD in this key market will provide local physicians and patients with greater access to comprehensive vascular intervention solutions and support Zylox-Tonbridge's continued expansion across Southeast Asia. Zylox-Tonbridge's overseas business has grown rapidly in recent years, generating approximately USD 3.1 million in revenue in 2024, with a four-year compound annual growth rate (CAGR) of 87%. The Company's business footprint spans Europe, the Americas, the Middle East, and Africa, covering countries such as France, Germany, Italy, Spain, Turkey, Saudi Arabia, Argentina, Brazil, and South Africa. In 2025, Zylox-Tonbridge showcased key products at major global congresses including LINC, PAIRS, CICE, and ESOC, boosting its international brand visibility. Looking ahead, Zylox-Tonbridge remains committed to its mission of "Innovation for Quality Life" and will continue expanding global access to high-quality, affordable treatment solutions through enhanced localization and strategic market entry. View original content: SOURCE ZYLOX-TONBRIDGE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
